Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zastaprazan by Onconic Therapeutics for Corrosive Esophagitis (Erosive Esophagitis): Likelihood of Approval
Zastaprazan is under clinical development by Onconic Therapeutics and currently in Phase III for Corrosive Esophagitis (Erosive Esophagitis). According to...
Zastaprazan by Onconic Therapeutics for Gastric Ulcers: Likelihood of Approval
Zastaprazan is under clinical development by Onconic Therapeutics and currently in Phase III for Gastric Ulcers. According to GlobalData, Phase...
Nesuparib by Onconic Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Nesuparib is under clinical development by Onconic Therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Nesuparib by Onconic Therapeutics for Fallopian Tube Cancer: Likelihood of Approval
Nesuparib is under clinical development by Onconic Therapeutics and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
Nesuparib by Onconic Therapeutics for Peritoneal Cancer: Likelihood of Approval
Nesuparib is under clinical development by Onconic Therapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
Nesuparib by Onconic Therapeutics for Epithelial Ovarian Cancer: Likelihood of Approval
Nesuparib is under clinical development by Onconic Therapeutics and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...